Miguel Forte, MD, PhD ISCT President mC4Tx Belgium The year 2024 was another great year for patients with unmet medical needs as strong progress was made with cell and gene therapy products. We saw 10 new product approvals in between Europe, with EMA, and the US with the FDA....
Miguel Forte, MD, PhD ISCT President mC4Tx Belgium Cell and gene therapy has come a long way, particularly since 2017 when the fantastic clinical outcomes and patient value that had been reported over the previous 5 year promised a great commercial opportunity with regulatory...
Miguel Forte, MD, PhD ISCT President mC4Tx Belgium Forty years ago, Steve Jobs made a visionary speech about the use of computers. People would be using computers all day long! He added that “people would be going to ask themselves, several years down the road, “if this was not always...
Jacques Galipeau, MD President, ISCT (2022-2024) Associate Dean for Therapeutics Development UW-Madison School of Medicine and Public Health The New York Times recently reported that Kendric Cromer, a 12-year-old boy in Washington, D.C., is the first commercial patient to begin the...
Jacques Galipeau, MD, MD FRCP(C) President, ISCT Associate Dean for Therapeutics Development University of Wisconsin School of Medicine and Public Health A few weeks ago, I gave the opening keynote address at the 2nd edition of the Dubai Stem Cell Conference (DSCC) chaired by...
There are hundreds of FACT and JACIE accredited clinical centers worldwide where thousands of dedicated technologists and their peer mates toil day-in, day-out in cell processing facilities supportive of hospital-based cell therapy programs. To this hospital-based workforce an ever-expanding...
Jacques Galipeau, MD FRCP(C) President, ISCT Don and Marilyn Anderson Professor in Oncology Associate Dean for Therapeutics Development University of Wisconsin School of Medicine and Public Health The ISCT ANZ recently concluded in August 2023 an extremely successful annual...
Jacques Galipeau, MD FRCP(C) President, ISCT Don and Marilyn Anderson Professor in Oncology Associate Dean for Therapeutics Development University of Wisconsin School of Medicine and Public Health Cell and Gene Therapies (CGTs), especially at the intersection of gene-modified...
Jacques Galipeau, MD FRCP(C) President, ISCT Don and Marilyn Anderson, Professor in Oncology Associate Dean for Therapeutics Development University of Wisconsin School of Medicine and Public Health The Cell and Gene Therapy (CGT) field has now repeatedly demonstrated that cells - as...
From the President’s Desk: Cell and Gene Therapies and air travel Closer than you think Jacques Galipeau, MD FRCP(C) President, ISCT Don and Marilyn Anderson Professor in Oncology Associate Dean for Therapeutics Development University of Wisconsin School of...